A
Acer Therapeutics Inc
F:P6NA
Acer Therapeutics Inc
F:P6NA
Price:
0.804
EUR
Market Closed
Market Cap:
€28.8m
Balance Sheet
Balance Sheet Decomposition
Acer Therapeutics Inc
Acer Therapeutics Inc
Balance Sheet Decomposition is not available for
Acer Therapeutics Inc
Acer Therapeutics Inc
Balance Sheet
Acer Therapeutics Inc
Acer Therapeutics Inc
Currency: USD
| Dec-2013 | Dec-2014 | Dec-2015 | Dec-2016 | Dec-2017 | Dec-2018 | Dec-2019 | Dec-2020 | Dec-2021 | Dec-2022 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | |||||||||||
| Cash & Cash Equivalents |
24
|
10
|
13
|
2
|
16
|
42
|
12
|
6
|
13
|
2
|
|
| Cash Equivalents |
24
|
10
|
13
|
2
|
16
|
42
|
12
|
6
|
13
|
2
|
|
| Total Receivables |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
5
|
0
|
|
| Accounts Receivables |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
5
|
0
|
|
| Other Receivables |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Inventory |
1
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Current Assets |
0
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
10
|
1
|
|
| Total Current Assets |
25
|
11
|
13
|
2
|
17
|
43
|
13
|
6
|
28
|
4
|
|
| PP&E Net |
1
|
1
|
1
|
0
|
0
|
0
|
1
|
1
|
0
|
0
|
|
| PP&E Gross |
1
|
1
|
1
|
0
|
0
|
0
|
1
|
1
|
0
|
0
|
|
| Accumulated Depreciation |
2
|
2
|
2
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Intangible Assets |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Goodwill |
0
|
0
|
0
|
0
|
8
|
8
|
8
|
8
|
8
|
8
|
|
| Other Long-Term Assets |
0
|
0
|
1
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Assets |
0
|
0
|
0
|
0
|
8
|
8
|
8
|
8
|
8
|
8
|
|
| Total Assets |
26
N/A
|
12
-55%
|
14
+22%
|
3
-81%
|
24
+780%
|
51
+108%
|
21
-58%
|
15
-32%
|
36
+148%
|
12
-68%
|
|
| Liabilities | |||||||||||
| Accounts Payable |
1
|
1
|
1
|
0
|
0
|
1
|
1
|
2
|
1
|
4
|
|
| Accrued Liabilities |
1
|
1
|
1
|
0
|
2
|
4
|
2
|
4
|
2
|
4
|
|
| Short-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Current Portion of Long-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
2
|
|
| Other Current Liabilities |
1
|
1
|
3
|
0
|
0
|
0
|
0
|
1
|
25
|
9
|
|
| Total Current Liabilities |
3
|
3
|
5
|
1
|
2
|
6
|
3
|
6
|
29
|
19
|
|
| Long-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
9
|
|
| Other Liabilities |
2
|
1
|
0
|
0
|
0
|
0
|
0
|
0
|
9
|
0
|
|
| Total Liabilities |
6
N/A
|
4
-23%
|
5
+10%
|
1
-83%
|
2
+148%
|
6
+175%
|
3
-44%
|
6
+106%
|
38
+494%
|
28
-25%
|
|
| Equity | |||||||||||
| Common Stock |
0
|
0
|
0
|
12
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Retained Earnings |
126
|
141
|
153
|
11
|
26
|
47
|
76
|
99
|
115
|
141
|
|
| Additional Paid In Capital |
147
|
148
|
163
|
1
|
48
|
92
|
95
|
107
|
113
|
124
|
|
| Total Equity |
21
N/A
|
7
-64%
|
10
+29%
|
2
-80%
|
22
+1 046%
|
45
+102%
|
18
-59%
|
8
-55%
|
2
N/A
|
17
-872%
|
|
| Total Liabilities & Equity |
26
N/A
|
12
-55%
|
14
+22%
|
3
-81%
|
24
+780%
|
51
+108%
|
21
-58%
|
15
-32%
|
36
+148%
|
12
-68%
|
|
| Shares Outstanding | |||||||||||
| Common Shares Outstanding |
0
|
0
|
1
|
6
|
8
|
10
|
10
|
13
|
14
|
20
|
|
Switch to:
Switch to:
See Also
Discover More
